Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Scott I. Bearman"'
Autor:
Roy B. Jones, Peter A. McSweeney, Jonathan A. Gutman, J. W. Sweetenham, Chan Zeng, Anna E. Barón, Y. Nieto, Elizabeth J. Shpall, Scott I. Bearman
Publikováno v:
Bone Marrow Transplantation. 36:443-451
We report outcomes in advanced lymphoma patients (n = 32) who enrolled in a trial of prospectively planned combined autologous/reduced-intensity transplantation (RIT) (n = 25) or who received RIT shortly after prior autografting because of high relap
Autor:
David A. Rizzieri, Yago Nieto, Elizabeth J. Shpall, Peter A. McSweeney, Scott I. Bearman, Steve Matthes, Anna E. Barón, Roy B. Jones, James J. Vredenburgh, C. Gasparetto, Nelson J. Chao
Publikováno v:
Clinical Cancer Research. 10:7136-7143
Purpose: To evaluate the safety of concurrent treatment with trastuzumab and high-dose chemotherapy (HDC), using cyclophosphamide, cisplatin, and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), with autologous hematopoietic progenitor cells support, in
Publikováno v:
Clinical Cancer Research. 10:2609-2617
Purpose: We described previously a prognostic model for high-risk primary breast cancer patients receiving high-dose chemotherapy (HDC). Such model included nodal ratio (no. involved nodes:no. dissected nodes), tumor size, hormone receptors, and HER2
Autor:
Thomas M. Grogan, Sarah Taylor, C. Harris Spiridonidis, Robert A. Chapman, Douglas W. Blayney, Michael LeBlanc, Thomas P. Miller, Richard I. Fisher, Scott I. Bearman, Ellen R. Gaynor
Publikováno v:
Journal of Clinical Oncology. 21:2466-2473
Purpose: To test the hypothesis that therapy of intermediate- and high-grade (excluding Burkitt lymphoblastic) lymphoma with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) could be safely dose-intensified with routine filgrastim su
Autor:
Betsy Blunk, Vicki Slat-Vasquez, Ian McNiece, Roger Giller, Anna E. Barón, E. Hild, Chan Zeng, Ralph Quinones, Christopher J. Hogan, Deborah Schissel, Peggy Russell, William Ward, Janet Malcolm, Elizabeth J. Shpall, Nancy E. Madinger, Brian M. Freed, Scott I. Bearman, Yago Nieto, Roy B. Jones
Publikováno v:
Biology of Blood and Marrow Transplantation. 8(7):368-376
Umbilical cord blood (CB) from unrelated donors is increasingly used to restore hematopoiesis after myeloablative therapy. CB transplants are associated with higher rates of delayed and failed engraftment than are bone marrow transplants, particularl
Autor:
Scott I. Bearman, Elizabeth J. Shpall, Rachel Rabinovitch, Roy B. Jones, Peter A. McSweeney, Yago Nieto, Pablo J. Cagnoni
Publikováno v:
Bone Marrow Transplantation. 28:1083-1086
A 51-year-old patient with refractory CLL elected to participate in a trial of nonmyeloablative trans- plantation from an HLA-matched unrelated donor. He received low-dose fludarabine/TBI, with infusion of donor PBPC and cyclosporin (CsA)/MMF. Early
Autor:
James Murphy, Judy Stoltz, Scott I. Bearman, John Ryder, Yago Nieto, Elizabeth J. Shpall, Janet McDermitt, Peggy Russell, Pablo J. Cagnoni, Wilbur A. Franklin, Roy B. Jones, Andrea Steele, Christopher J. Hogan, Ian McNiece
Publikováno v:
Blood. 96:3001-3007
Ex vivo expanded peripheral blood progenitor cells (PBPCs) have been proposed as a source of hematopoietic support to decrease or eliminate the period of neutropenia after high-dose chemotherapy. CD34 cells were selected from rhG-CSF mobilized PBPCs
Autor:
Pablo J. Cagnoni, Yago Nieto, Peggy Russell, Elizabeth J. Shpall, Roy B. Jones, Bret Cook, James Murphy, Ronit Yerushalmi, Janet McDermit, Scott I. Bearman, Samia Nawaz
Publikováno v:
Journal of Clinical Oncology. 18:2070-2080
PURPOSE: To ascertain the predictive value of Her-2/neu overexpression and p53 mutations, assessed by immunohistochemistry, in high-risk primary breast cancer (HRPBC) treated with high-dose chemotherapy (HDCT). PATIENTS AND METHODS: We obtained paraf
Autor:
Scott I. Bearman
Publikováno v:
Cancer Investigation. 18:494-497
Publikováno v:
Bone Marrow Transplantation. 24:1-4
Interpatient variability in exposure to certain chemotherapy agents can influence patient outcome, particularly with high-dose chemotherapy. We evaluated the possibility of a pharmacokinetic (PK) drug-drug interaction between the antiemetic agents an